Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021

In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant–dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Glatman-Freedman, Aharona, Hershkovitz, Yael, Kaufman, Zalman, Dichtiar, Rita, Keinan-Boker, Lital, Bromberg, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2021
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544958/
https://www.ncbi.nlm.nih.gov/pubmed/34570694
http://dx.doi.org/10.3201/eid2711.211886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544958/
https://www.ncbi.nlm.nih.gov/pubmed/34570694
http://dx.doi.org/10.3201/eid2711.211886

Ejemplares similares